Please use this identifier to cite or link to this item: https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3870
Journal Title: Targeting homologous recombination deficiency in uterine leiomyosarcoma
Authors: Collins, Ian M.
Dall, Genevieve
Vandenberg, Cassandra J.
Nesic, Ksenija
Ratnayake, Gayanie
Zhu, Wenying
Vissers, Joseph H. A.
Bedo, Justin
Penington, Jocelyn
Wakefield, Matthew J.
Kee, Damien
Carmagnac, Amandine
Lim, Ratana
Shield-Artin, Kristy
Milesi, Briony
Lobley, Amanda
Kyran, Elizabeth L.
O'Grady, Emily
Tram, Joshua
Zhou, Warren
Nugawela, Devindee
Stewart, Kym Pham
Caldwell, Reece
Papadopoulos, Lia
Ng, Ashley P.
Barker, Holly E.
Dobrovic, Alexander
Fox, Stephen B.
McNally, Orla
Power, Jeremy D.
Meniawy, Tarek
Han Tan, Teng
Klein, Oliver
Barnett, Stephen
Olesen, Inger
Hamilton, Anne
Hofmann, Oliver
Grimmond, Sean
Papenfuss, Anthony T.
Scott, Clare L.
SWH Author: Collins, Ian M.
Klein, Oliver
Keywords: Cancer
Leiomyosarcoma
Uterine
Gynaecology
uLMS
DNA
Issue Date: 4-May-2023
Date Accessioned: 2023-05-11T23:38:09Z
Date Available: 2023-05-11T23:38:09Z
Accession Number: 112
Url: https://jeccr.biomedcentral.com/articles/10.1186/s13046-023-02687-0
Description Affiliation: SouthWest Healthcare, Warrnambool, VIC, 3280, Australia
Walter and Eliza Hall Institute of Medical Research, Parkville, VIC, 3052, Australia
Department of Medical Biology, University of Melbourne, Parkville, VIC, 3052, Australia
Royal Women’s Hospital, Parkville, VIC, 3052, Australia
Centre for Cancer Research and Department of Clinical Pathology, University of Melbourne, Parkville, VIC, 3010, Australia
School of Computing and Information Systems, the University of Melbourne, Parkville, VIC, 3010, Australia
Olivia Newton-John Cancer Research Institute, Heidelberg, VIC, 3084, Australia
Austin Health, Heidelberg, VIC, 3084, Australia
Australian Rare Cancer Portal, BioGrid Australia, Melbourne Health, Parkville, VIC, 3052, Australia
Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, The University of Melbourne, Victoria, 3010, Australia
Royal Melbourne Hospital, Parkville, VIC, 3052, Australia
Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC, 3010, Australia
Launceston General Hospital, Launceston, TAS, 7250, Australia
University of Western Australia, Perth, WA, 6009, Australia
SouthWest Healthcare, Warrnambool, VIC, 3280, Australia
Faculty of Health, School of Medicine, Deakin University, Warrnambool, VIC, 3280, Australia
Western Hospital, Footscray, VIC, 3011, Australia
University Hospital Geelong, Geelong, VIC, 3220, Australia
Source Volume: 42
Issue Number: 112
DOI: 10.1186/s13046-023-02687-0
Date: 2023
Abstract: Uterine leiomyosarcoma (uLMS) is a rare and aggressive gynaecological malignancy, with individuals with advanced uLMS having a five-year survival of < 10%. Mutations in the homologous recombination (HR) DNA repair pathway have been observed in ~ 10% of uLMS cases, with reports of some individuals benefiting from poly (ADP-ribose) polymerase (PARP) inhibitor (PARPi) therapy, which targets this DNA repair defect. In this report, we screened individuals with uLMS, accrued nationally, for mutations in the HR repair pathway and explored new approaches to therapeutic targeting.
URI: https://repository.southwesthealthcare.com.au/swhealthcarejspui/handle/1/3870
Journal Title: Journal of Experimental & Clinical Cancer Research
ISSN: 1756-9966
Type: Journal Article
Appears in Collections:SWH Staff Publications



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.

Google Media

Google ScholarTM

Who's citing